Evidence map›Paper›PMID 31345158›Full record

ArticleBMC nephrology2019

Systemic sclerosis medications and risk of scleroderma renal crisis.

S M Gordon, J B Hughes, R Nee, R S Stitt, W T Bailey, D J Little, J D Edison, S W Olson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Kidney Involvement in Systemic Sclerosis.Journal of personalized medicine · 2022
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. The Ubiquitin Proteasome System and Skin Fibrosis.Molecular diagnosis & therapy · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

S M GordonNephrology Department, Walter Reed National Military Medical Center, 8901 Rockville Pike, Bethesda, MD, 20889, USA.
J B HughesDepartment of Medicine, Walter Reed National Military Medical Center, 8901 Rockville Pike, Bethesda, USA.
R NeeNephrology Department, Walter Reed National Military Medical Center, 8901 Rockville Pike, Bethesda, MD, 20889, USA.
R S StittRheumatology Department, Walter Reed National Military Medical Center, 8901 Rockville Pike, Bethesda, USA.
W T BaileyRheumatology Department, Walter Reed National Military Medical Center, 8901 Rockville Pike, Bethesda, USA.
D J LittleNephrology Department, Walter Reed National Military Medical Center, 8901 Rockville Pike, Bethesda, MD, 20889, USA.
J D EdisonRheumatology Department, Walter Reed National Military Medical Center, 8901 Rockville Pike, Bethesda, USA.
S W OlsonNephrology Department, Walter Reed National Military Medical Center, 8901 Rockville Pike, Bethesda, MD, 20889, USA. Stephen.w.olson.mil@mail.mil.
Walter Reed National Military Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundScleroderma Renal Crisis (SRC) is associated with significant morbidity and mortality. While prednisone is strongly associated with SRC, there are no previous large cohort studies that have evaluated ace inhibitor (ACEi) calcium channel blocker (CCB), angiotensin receptor blocker (ARB), endothelin receptor blocker (ERB), non-steroidal anti-inflammatory drug (NSAID), fluticasone, or mycophenolate mofetil (MMF) use in systemic sclerosis (SSc) and the risk of SRC.

methodsIn this retrospective cohort study of the entire military electronic medical record between 2005 and 2016, we compared the use of ACEi, ARB, CCB, NSAID, ERB, fluticasone, and MMF after SSc diagnosis for 31 cases who subsequently developed SRC to 322 SSc without SRC disease controls.

resultsACEi was associated with an increased risk for SRC adjusted for age, race, and prednisone use [odds ratio (OR) 4.1, 95% confidence interval (CI) 1.6-10.2, P = 0.003]. On stratified analyses, ACEi was only associated with SRC in the presence [OR 5.3, 95% CI 1.1-29.2, p = 0.03], and not the absence of proteinuria. In addition, a doubling of ACEi dose [61% vs. 12%, p < 0.001) and achieving maximum ACEi dose [45% vs. 4%, p < 0.001] after SSc diagnosis was associated with future SRC. CCB, ARB, NSAIDs, ERB, fluticasone, and MMF use were not significantly associated with SRC.

conclusionACEi use at SSC diagnosis was associated with an increased risk for SRC. Results suggest that it may be a passive marker of known SRC risk factors, such as proteinuria, or evolving disease. SSC patients that require ACEi should be more closely monitored for SRC.

Indexed as

Acute Kidney InjuryAdultCohort StudiesFemaleHumansHypertension, RenalMaleMiddle AgedRetrospective StudiesRisk AssessmentScleroderma, SystemicACE inhibitor, proteinuriaRisk factorsScleroderma renal crisisSystemic sclerosis

Identifiers

PMID31345158
PMCPMC6659266
OpenAlexW2964285510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.